ALL
Aristocrat had a good result today, comfortably ahead of consensus on most metrics.
Generally speaking, it is quite a cyclical business, not so much because of how the industry revenues move with GDP, but rather due to idiosyncratic reasons, like the ebb and flow of popular games that grab and hold consumer attention.

And, at the moment, the games ALL have are quite popular, with the headlines being Top 17 out of 25 premium leased.

It takes a lot of money to R&D the kinds of games that are going to be popular, and also costs a lot of money to market them successfully. Pretty normal for a business, but it does give rise to the idea that revenues and earnings for ALL can be quite volatile.

COVID was, unlike most recessions, deeply unusual in that casinos, normally quite defensive to downturns, were closed, and so revenue models which have a “fee per day” type arrangement (there’s lot of inputs to how they get paid, but that’s a part of it) are effected if games are switched off and gaming venues are closed.
That’s why ALL was a “COVID recovery” stock, rather than a “COVID beneficiary”, as you might well have initially first thought.

The financials look good, with low gearing (thanks to the acquisition related equity raise) and strong cashflows (not shown, as Bloomberg takes a little while to update the newly reported numbers).
The acquisition of Playtech, subject to approval (shareholders, rival bids, legal and regulatory), is sensible in the low interest rate environment. Now is the time to go big.
As with many stocks of late, valuation metrics are fairly expensive, 30x forward earnings, but perhaps not outrageously so.

Not one we own, but executing well, and worth watching.
Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Please note that past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.